Behçet's disease and thrombophilia

Annals of the Rheumatic Diseases

Volumn 60, Issue 12, 2001, Pages 1081-1085

  Leiba, M ^a   Sidi, Y ^a   Gur, H ^a   Leiba, A ^a   Ehrenfeld, M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BEHCET DISEASE; BLOOD CLOTTING; ENDOTHELIUM INJURY; FIBRINOLYSIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

BEHCET SYNDROME; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; THROMBOPHILIA;

EID: 0035178837     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.60.12.1081     Document Type: Review

References (57)

1. The person behind the eponym: Hulusi Behçet (1889-1948)
2. Behçet's disease. New preparation on an enigmatic syndrome
3. Vascular involvement in Behçet's disease
4. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease
5. Vascular involvement in Behçet's disease: 8 year audit
6. Abnormalities in protein C anticoagulant pathway detected by a novel assay using human thrombomodulin
7. Von Willebrand factor in Behçet's disease
8. Practical treatment recommendations for pharmacotherapy in Behçet's syndrome
9. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay
10. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population
11. Behçet's disease as a prethrombotic state
12. Haemostatic markers of procoagulant imbalance in Behçet's disease
13. Behçet's disease
14. Behçet's disease in Saudi Arabia
15. Thoracic involvement in Behçet's disease: Pathologic, clinical, and imaging features
16. Impaired haemostatic kinetics and endothelial function in Behçet's disease
17. Circulating thrombomodulin as a clue of endothelial damage in Behçet's disease
18. Vasculo-Behçet's disease: Immunological study of the formation of aneurysm
19. Activated protein C resistance in Behçet's disease
20. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome
21. Defective fibrinolysis in Behçet's syndrome: Signifcance and possible mechanism
22. Arterial lesions in Behçet's disease. A study in 25 patients
23. Coagulation and fibrinolytic activity in Behçet's disease
24. Haemostasis in patients with Behçet's disease
25. Lp (a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease
26. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cell
27. Coagulation and fibrinolytic activity in Behçet's disease
28. Antithrombin III, protein C and protein S plasma levels in patients with Behçet's disease
29. Thrombophilic factors and their relation to thromboembolic and other clinical manifestation in Behçet's disease
30. Comparison of coagulation parameters for healthy subjects and Behçet's disease patients with and without vascular involvment
31. Thrombomodulin levels in Behçet's disease with and without factor V Leiden mutation
32. Behçet's disease, endothelium and thrombosis
33. Resistance to activated protein C as a basis for venous thrombosis
34. Mutation in bood coagulation factor V associated with resistance to activated protein C
35. Association of factors V Leiden with Behçet's disease
36. Factor V leiden mnutation in patients with Behçet's disease
37. Factor V Leiden mutation is associated with ocular involvement in Behçet's disease
38. The concept and classification of antiphospholipid/cofactor syndromes
39. Anti-prothrombin but not 'pure' anticardiolipin antibodies are associated with the clinical features of the antiphospholipid antibodies syndrome
40. Antiphospholipid antibodies and thrombosis
41. Anticardiolipin antibodies in adamantiades - Behçet's disease
42. Anticardiolipin antibodies: Occurrence in Behçet's s syndrome
43. Association of anticardiolipin antibodies with vascular thrombosis and neurological manifestation of Behçet's disease
44. Anticardiolipin antibodies in Behecet's disease
45. Anticardiolipin antibodies and retinal vascular complications in Behçet's disease
46. Markers of vascular injury in Behçet's disease associated with retinal vasculitis
47. Is there a role for antiphospholipid binding protein antibodies in the pathogenesis of thrombosis in Behçet's disease?
48. Anticardiolipin antibodies in Behçet's disease: A reassessment
49. Thrombosis and antithromboric therapy
50. Hyperhomocystinemia and activated protein C resistance in Behçet's disease
51. Evaluation of hypercoagulable state
52. A common genetic variation in 3'-untranslated region of prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
53. The prothrombin 20210 G to A variation and thrombosis
54. Prothrombin gene 20210 G - A mutation in the Turkish population
55. Prothrombin gene 20210 G - A mutation in Turkish patients with thrombosis
56. Procoagulant mutations and venous thrombosis in Behçet's disease
57. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutation on deep venous thrombogenesis in Behçet's disease